Suzman DL - Search Results

1

Highlights of FDA Oncology Approvals in 2023: Bispecific T-cell Engagers, Pediatric Indications, and Inclusive Drug Development.

Donaldson JM, Seddiq M, Fusco MJ, Singla S, Pamuk GE, Lee-Alonso RJ, Mixter BD, Goldberg KB, Amiri-Kordestani L, de Claro RA, Drezner N, Gormley NJ, Kanapuru B, Lemery SJ, Fashoyin-Aje LA, Richardson NC, Singh H, Suzman DL, Theoret MR, Kluetz PG, Pazdur R. Donaldson JM, et al. Among authors: suzman dl. Cancer Discov. 2023 Dec 12;13(12):2515-2524. doi: 10.1158/2159-8290.CD-23-1226. Cancer Discov. 2023. PMID: 38084090

2

PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.

Markowski MC, Chen Y, Feng Z, Cullen J, Trock BJ, Suzman D, Antonarakis ES, Paller CJ, Rosner I, Han M, Walsh PC, Partin AW, Eisenberger M. Markowski MC, et al. Clin Genitourin Cancer. 2019 Dec;17(6):470-475.e1. doi: 10.1016/j.clgc.2019.08.002. Epub 2019 Aug 21. Clin Genitourin Cancer. 2019. PMID: 31530439 Free PMC article.

3

Bone-targeting agents in prostate cancer.

Suzman DL, Boikos SA, Carducci MA. Suzman DL, et al. Cancer Metastasis Rev. 2014 Sep;33(2-3):619-28. doi: 10.1007/s10555-013-9480-2. Cancer Metastasis Rev. 2014. PMID: 24398856 Free PMC article. Review.

4

Sustained remission and reversal of end-organ dysfunction in a patient with anaplastic myeloma.

Agrawal M, Kanakry J, Arnold CA, Suzman DL, Mathieu L, Kasamon YL, Gladstone DE, Ambinder RF, Ghosh N. Agrawal M, et al. Among authors: suzman dl. Ann Hematol. 2014 Jul;93(7):1245-6. doi: 10.1007/s00277-013-1950-7. Ann Hematol. 2014. PMID: 24232305 Free PMC article. No abstract available.

5

Determining the optimal treatment for metastatic castration-resistant prostate cancer: age should not be a factor.

Suzman DL, Eisenberger MA. Suzman DL, et al. Eur Urol. 2014 May;65(5):884-6. doi: 10.1016/j.eururo.2013.10.002. Epub 2013 Oct 16. Eur Urol. 2014. PMID: 24157242 Free PMC article. No abstract available.

6

Beyond approval: what is the most appropriate way to use the expanding Armamentarium in metastatic castration-resistant prostate cancer and how do we move forward?

Suzman D, Eisenberger M. Suzman D, et al. Eur Urol. 2014 Nov;66(5):826-8. doi: 10.1016/j.eururo.2014.03.046. Epub 2014 Apr 13. Eur Urol. 2014. PMID: 24751214 No abstract available.

7

Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.

Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES. Suzman DL, et al. Prostate. 2014 Sep;74(13):1278-85. doi: 10.1002/pros.22844. Epub 2014 Jul 22. Prostate. 2014. PMID: 25053178 Free PMC article.

8

Castration-resistant prostate cancer: latest evidence and therapeutic implications.

Suzman DL, Antonarakis ES. Suzman DL, et al. Ther Adv Med Oncol. 2014 Jul;6(4):167-79. doi: 10.1177/1758834014529176. Ther Adv Med Oncol. 2014. PMID: 25057303 Free PMC article. Review.

9

In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis.

Suzman DL, Antonarakis ES. Suzman DL, et al. Oncology (Williston Park). 2014 Oct;28(10):880, 882. Oncology (Williston Park). 2014. PMID: 25323614 Free article. No abstract available.

10

High-dose itraconazole as a noncastrating therapy for a patient with biochemically recurrent prostate cancer.

Suzman DL, Antonarakis ES. Suzman DL, et al. Clin Genitourin Cancer. 2014 Apr;12(2):e51-3. doi: 10.1016/j.clgc.2013.11.015. Epub 2013 Nov 14. Clin Genitourin Cancer. 2014. PMID: 24332506 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

53 results

Search Page

Filters